Bio Protech, Inc.
KKRX:199290410.00
KRW
+10.00
(+2.50%)
ISIN
KR7199290008
Return %
Stock
S&P 500
1Y
-8.89
14.39
3Y
-70.33
81.42
5Y
-86.01
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- Full Time Employees
- 118
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Wonju-si South Korea
- IPO Date
- Dec 8, 2016
- Website
- protechsite.com
- Similar Companies
- Business
- Bio Protech, Inc. is a South Korea-based medical device manufacturer specializing in the development, fabrication, and global distribution of disposable medical electrodes, electrosurgical instruments, and physiological monitoring accessories. Founded in 2000 and headquartered in Wonju, Gangwon-do, South Korea, the company operates within the healthcare equipment and supplies sector, catering to hospitals, ambulatory surgical centers, emergency response organizations, and medical supply distributors across more than 40 international markets. Bio Protech maintains direct international operations and production facilities through subsidiaries including Bio Protech USA Inc. in the United States and Bio Protech Yantai Inc. in China, with parent company shares publicly traded on the Korea Exchange KONEX market under the ticker symbol 199290. The company offers a comprehensive portfolio organized into distinct product categories: electrosurgical devices and accessories, including the PROPENCIL series of disposable electrosurgical pencils with integrated tissue cutting, coagulation, and smoke evacuation capabilities; the PROPLATE series of conductive hydrogel dispersive grounding pads designed to eliminate surgical burn risks; cardiac diagnostic and monitoring electrodes, including the TELECTRODE line of silver/silver-chloride electrocardiogram monitoring electrodes, PRO-TAB resting tab electrodes, and PRO-NEO neonatal electrodes; therapeutic stimulation consumables, including PRO TENS and neuromuscular electrical stimulation carbon-film electrode pads for physical therapy and pain management; emergency life-support consumables, consisting of PRO-PAD multifunction defibrillation electrodes compatible with automated external defibrillators and clinical manual units; and patient monitoring accessories, encompassing OXI-PRO pulse oximeter SpO2 sensors, electromyography needle electrodes, and surgical blades. In recent corporate developments, Bio Protech has executed capital structure adjustments by extending the maturity of its eleventh series convertible bonds to July 2028, reinforcing financial flexibility and long-term liquidity. Backed by institutional investor Metistone Growth PEF as its primary shareholder, the company has driven an operational turnaround, achieving renewed operating profitability while expanding manufacturing throughput and scaling international market penetration for its specialized surgical smoke evacuation systems and advanced electrosurgical product lines across North America, Europe, and Asia.